key: cord-0808139-1t4zsqrs
authors: Huang, Zoufang; Xie, Jiangbo
title: Ruxolitinib in conjunction with the HLH-94 protocol for Epstein-Barr virus-related hemophagocytic lymphohistiocytosis in the intensive care unit: A case report
date: 2021-03-19
journal: Medicine (Baltimore)
DOI: 10.1097/md.0000000000025188
sha: 5ba6b9184294000621f8979a53eb0ba248dcf61e
doc_id: 808139
cord_uid: 1t4zsqrs

RATIONALE: The HLH-94 protocol is a standard induction treatment for hemophagocytic lymphohistiocytosis. However, about 30% of patients may not respond. Ruxolitinib has been clinically proven to be an effective treatment for hemophagocytic lymphohistiocytosis (HLH). PATIENT CONCERNS: A previously healthy 14-year-old girl presented to the local hospital with a 4-day history of persistent fever and sore throat. DIAGNOSIS: Clinical and laboratory tests revealed fever >38.5°C, hepatosplenomegaly, pancytopenia, hypertriglyceridemia, hypofibrinogenemia, hyperferritinemia, and an elevated interleukin-2 receptor level. INTERVENTION: This patient was treated with ruxolitinib and the HLH-94 protocol. OUTCOMES: The patient's clinical and some laboratory indices improved. Unfortunately, vital signs such as respiratory function and consciousness did not improve. LESSONS: This case report highlights the effect of using ruxolitinib in conjunction with the HLH-94 protocol. However, safety evaluation of this regimen was not performed because critically ill patient died too fast.

Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening disorder characterized by an excessive inflammatory response mediated by hyperactivation of T cells and antigen-presenting cells. Epstein-Barr virus (EBV) is a common triggering factor for HLH. EBV-associated HLH (EBV-HLH) can progress rapidly to multiorgan dysfunction. Symptoms of HLH include persistent pyrexia, pancytopenia, hepatosplenomegaly, elevated lactate dehydrogenase, serum ferritin, and triglyceride levels, and decreased fibrinogen. [1, 2] The HLH-94 protocol is a standard induction treatment for HLH, consisting of dexamethasone and etoposide. [3] However, about 30% of patients may not respond. [4] Ruxolitinib has been clinically proven to be effective to treat HLH. [5] [6] [7] Thus, we use ruxolitinib in conjunction with the HLH-94 protocol as the first-line treatment.

Here we report a case of a patient with newly diagnosis EBVtriggered HLH who was critically ill and experienced improvement after ruxolitinib in conjunction with the HLH-94 protocol.

The patient's family had provided informed consent for the publication of this case report.

A previously healthy 14-year-old girl presented to the local hospital with a 4-day history of persistent fever and sore throat. After taking acetaminophen for 2 days, she felt worse and complained of extremity myalgia. Laboratory tests revealed pancytopenia (white blood cell [WBC] count, 2.69 Â 10 9 /L; neutrophil count, 1.96 Â 10 9 /L; hemoglobin, 93 g/L; platelet count, 34 Â 10 9 /L), abnormal liver function (aspartate amino- Meropenem and vancomycin treatment was initiated within 3 days of admission, and a chest computed tomography (CT) scan revealed pneumonia. On hospital day 2, thrombotic thrombocytopenic purpura was suspected. Dexamethasone 10 mg/day, intravenous immunoglobulin 0.4 g/kg/day, and plasmapheresis were administered. Her condition worsened, with a persistent fever of 38.5 to 39.8°C and rapid heart rate of >140 bpm. Her blood pressure was about 90/60 mm Hg, and she was supported with 1.6 mg/hour norepinephrine. She received mechanical ventilation because of respiratory failure. Platelets and fibrinogen were not elevated after an infusion. She had persistent epistaxis and coma on hospital day 3. Rheumatological, autoimmune, and oncological workups revealed no positive results (Table 1) . EBV polymerase chain reaction revealed 1.03 Â 10 6 copies/ml. Metagenomic next-generation sequencing (NGS) was positive for EBV but negative for bacteria, fungus, parasites, and Mycobacterium. Lactate dehydrogenase (LDH) was 3560 U/L. The patient met all 8 criteria for HLH, that is, fever >38.5°C, hepatosplenomegaly (based on Doppler ultrasound and abdominal CT), pancytopenia (WBC count, 0.67 Â 10 9 /L, hemoglobin, 67 g/L; platelet count, 2 Â 10 9 /L), hypertriglyceridemia (5.89 g/L), hypofibrinogenemia (0.72 g/L), hyperferritinemia (100,096 ng/ml), elevated interleukin-2 receptor level (40,740 U/ml), and hemophagocytosis observed on a bone marrow biopsy specimen. Genetic testing was performed and was negative for any known mutations causing HLH.

After confirming the diagnosis on hospital day 4, ruxolitinib (10 mg twice per day) was administered in conjunction with the HLH-94 protocol (Fig. 1 ). Her temperature returned to normal and the heart rate dropped to about 105 bpm after 20 hours ( Fig. 2A) . Her blood pressure returned to normal after administering 0.2 mg/hour norepinephrine. Improvements were seen in several indices, including the WBC count (Fig. 2B) , platelet count (Fig. 2C) , and fibrinogen level (Fig. 2D ). Her platelet count increased to 53 Â 10 9 /L after infusion. Her fibrinogen level returned to normal, and there was a normal prothrombin time and activated partial thromboplastin. D-dimer decreased from 125 mg/L to 2.5 mg/L. EBV dropped to 2.35 Â 10 4 copies/ml on hospital day 6. However, LDH and serum ferritin levels increased to 6,442 U/L and 42,897 ng/ml on hospital day 7, respectively. She remained in a coma on mechanical ventilation with high flow oxygen. On hospital day 8, her blood cell count decreased again (WBC count, 0.02 Â 10 9 /L; hemoglobin, 80 g/L; platelet count, 2 Â 10 9 /L). On hospital day 10, we utilized the DEP protocol (20 mg liposomal doxorubicin, 100 mg etoposide, and 500 mg methylprednisone) rather than the HLH94 protocol. She died of cardiac arrest at 11 PM that day. 

HLH is a fatal clinical syndrome and no optimal treatment is available for HLH, the mortality rate for which exceeds 40% in children and adults even when following the standard HLH-94 protocol. [2, 8] Clinicians have tried other combinations of agents. Ruxolitinib is a promising agent due to its powerful calming effect on the cytokine storm. [9] Ruxolitinib is a Janus kinase 1/2 inhibitor that suppresses the transmission of cytokine-induced signals. It suppresses cytokine signaling pathways, such as those of interferon (IFN)-g and interleukin-2. In murine models of HLH, mice who received ruxolitinib had improved survival, due to reversal of pancytopenia and splenomegaly, and reductions in proinflammatory cytokines and the number of CD8+ T cells. [10, 11] Ruxolitinib also reduces the severity of inflammation-associated anemia, and the number and activation status of T cells and neutrophils in primary and secondary HLH murine models, but only the IFN-g-neutralizing antibody reduces anemia severity. [12] Ruxolitinib increased the apoptotic potential of CD8 + T cells in a murine model and primary patient samples, which were resistant to dexamethasone. [13] In the human body, ruxolitinib has been demonstrated to exert a dramatic effect in some acute inflammatory syndromes, including acute graft-vs-host disease, [14] steroid-refractory cytokine release syndrome, [15] and COVID-19 with severe systemic hyperinflammation. [16] As a single drug, ruxolitinib has been used in salvage therapy for HLH, and exerted a powerful effect in several case reports. [17] [18] [19] [20] [21] Similar to what we observed in our case, the first reported case was a 38-year-old woman diagnosed as secondary HLH caused by an EBV infection. This patient exhibited improving disease markers but died eventually. [17] The improving markers included ferritin, fibrinogen, and LDH concentrations, but not pancytopenia. However, a 26-year-old woman diagnosed with treatment-refractory HLH caused by EBV and acute hepatitis C virus infection achieved completely recovery after the use of ruxolitinib. [19] In a series of children cases reported in China, the authors reported poor response to ruxolitinib alone in EBV-HLH when compared with other causes of HLH. [20] The authors suggested that ruxolitinib might not be able to eradicate EBV because EBV does not solely rely on JAK-STAT pathway to cause HLH. Therefore, combination with other drugs is needed.

Small series have reported improved clinical outcomes using ruxolitinib in conjunction with the HLH-94 protocol or chemotherapy. [6, 22, 23] In a multicenter, nonrandomized, phase II trial for refractory/relapsed HLH (NCT03533790), 54 patients received ruxolitinib combined with the doxorubicin-etoposide-methylprednisolone regimen for 2 weeks. Excitingly, in the patients who had previously received the DEP regimen but showed no improvement, 7 of 12 (58·3%) exhibited a partial response. [23] A pilot trial with first-line ruxolitinib as a single agent reported responses in 5 patients (NCT02400463), and the 2-month overall survival rate was 100%. [7] However, EBV-associated HLH was excluded from that trial. The most exciting outcome of ruxolitinib as a single agent for EBV-associated HLH was a 100% response rate (complete response, 75%, partial response, 25%) in a Chinese trial (ChiCTR2000029977). [5] Three cases treated with firstline ruxolitinib plus HLH-94 protocol showed rapid response and no obvious adverse effects. [6] For our patient who was treated with ruxolitinib plus HLH-94 protocol for the first line, clinical and some laboratory indices improved. Unfortunately, the vital signs, such as respiratory function and consciousness, did not improve.

Resources: Jiangbo Xie. Writingoriginal draft: Zoufang Huang. Writingreview & editing: Jiangbo Xie.

HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis

Adult haemophagocytic syndrome

HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society

Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation

Figure 2. The patient's treatment response. The temperature returned to normal and the heart rate dropped to about 105 bpm after 20 hours (A)

A pilot study of ruxolitinib as a front-line therapy for 12 children with secondary hemophagocytic lymphohistiocytosis

Low dose ruxolitinib plus HLH-94 protocol: a potential choice for secondary HLH

Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, singlecentre, pilot trial

Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol

Calming the storm in HLH

Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis

Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice

Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis

JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation

Ruxolitinib in corticosteroidrefractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey

Adjuvant ruxolitinib therapy relieves steroidrefractory cytokine-release syndrome without impairing chimeric antigen receptor-modified T-cell function

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation

Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: first case report

Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis

Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1/2 inhibitor ruxolitinib

Short-term effectiveness of ruxolitinib in the treatment of recurrent or refractory hemophagocytic lymphohistiocytosis in children

Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: a case series

Ruxolitinib combined with doxorubicin, etoposide, and dexamethasone for the treatment of the lymphomaassociated hemophagocytic syndrome

Ruxolitinib-combined doxorubicinetoposide-methylprednisolone regimen as a salvage therapy for refractory/relapsed haemophagocytic lymphohistiocytosis: a single-arm, multicentre, phase 2 trial

Editor: Maya Saranathan.The authors have no conflicts of interests to disclose.The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.